Kornimate/medical-research-clean huggingface dataset:
remote game-based exercise program for cognitive and motor function improvement

Conditions: Mild Cognitive Impairment; Dementia; Cognitive Impairment; Memory Loss

Summary: as our population ages, more older adults face motor-cognitive declines, increasing their risk of falls and fear of falling. exercise is an effective way to maintain cognitive function, as supported by recent studies. however, those with poor motor and cognitive abilities often struggle to visit rehabilitation centers, leading to high dropout rates and low adherence to unsupervised programs. a remote exercise program tailored for individuals with cognitive impairments is urgently needed to preserve cognitive function, promote independent living, and reduce related costs. researchers aim to develop an in-home system for adults with mild cognitive issues or dementia, designed to improve balance and cognition while being remotely supervised through telemedicine.

this study aims to develop and validate a remote exercise intervention for individuals at risk of or experiencing dementia using a wearable sensor-enabled platform, called tele-exergame. this approach could preserve cognitive function, promote independent living, reduce costs related to cognitive-motor decline, and advance remote technology use for screening cognitive and motor performance in older adults. the findings are crucial for healthcare providers, clinicians, seniors, and caregivers. 100 participants will be randomly assigned to either the intervention or control group, both undergoing a 12-week daily home exercise program for at least cumulative active exercise of 30 minutes per week twice weekly. the intervention group will complete sessions remotely using tele-exergame, while the control group will participate in home-based exercise without technology.

Eligibility criteria:
inclusion criteria: * adults with diagnosed with dementia or cognitive impairment * living independently in a residential home with a caregiver/informant * able to walk at least 30 feet with or without assistance exclusion criteria: * immobility or major mobility disorder or inability to engage safely in the proposed weight-bearing exercise program * diagnosed with severe cognitive impairment (moca score \< 16) * subjects with major hearing/visual impairment

Keywords: tele-exercise exergame tele-rehabilitation telehealth telemedicine virtual reality
acupuncture treatment of chronic obstructive pulmonary disease (copd) exacerbation

Conditions: COPD Exacerbation

Summary: chronic obstructive pulmonary disease (copd) is a major health problem. acute exacerbations are a health-care burden involving frequent hospitalizations and elevated costs. they have effective therapies with significant side effects. acupuncture has been shown to reduce dyspnea and other copd-related symptoms. the investigators will compare the efficacy and safety of the addition of true acupuncture to usual care with both sham-acupressure added to usual care and usual care only for the treatment of acute exacerbations of copd among inpatients.

this is an assessor-blinded randomized controlled trial in the setting of a tertiary academic medical center in israel. patients with clinical diagnosis of acute exacerbation of copd will be randomized to either usual care only, usual care with true acupuncture or usual care with sham-acupressure. the primary outcome will be clinical improvement of dyspnea as measured by mborg scale. secondary outcomes included improvement of other patient-reported outcomes and physiologic features, as well as duration of hospitalization and treatment failure. acupuncture-related side effects will be evaluated by the validated acupuncture adverse events (acupae) questionnaire.

Eligibility criteria:
inclusion criteria: * previous diagnosis of copd * clinical diagnosis of acute exacerbation of copd * informed consent exclusion criteria: * hemodynamic instability * platelet count \< 20 x 10\^9/l * expected respiratory deterioration requiring mechanical ventilation in the next 24 hours
be study of naftifine hcl

Conditions: Tinea Pedis

Summary: the current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. the study duration for each patient was 6 weeks: following were the visit details. v1-baseline and randomization visit (day 1). v2- end of therapy visit (at the end of week 2 + 2 days). v3- follow up visit (at the end of week 4 + 2 days). v4 - test of cure visit ( at the end of week 6 + 4 days).


Eligibility criteria:
inclusion criteria: 1. healthy males and females aged more than or equal to 18 years 2. clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin), and provisionally confirmed at baseline by a positive potassium hydroxide (koh) wet mount preparation (i.e., skin scrapings from the target site are placed on a microscope slide with a drop of 10% koh, and microscopic examination reveals segmented fungal hyphae) 3. the sum of the clinical signs and symptoms scores of the target lesion is at least 4, including a minimum score of at least 2 for erythema and a minimum score of 2 for either scaling or pruritus (on a scale of 0-3, where 2 indicates moderate severity) exclusion criteria: 1. pregnant or lactating or planning to become pregnant during the study period 2. use of antipruritics, including antihistamines, within 72 hours prior to entry into the study 3. use of topical corticosteroid, antibiotics or antifungal therapy within 2 weeks prior to entry into the study 4. use of systemic (e.g., oral or injectable) corticosteroid, antibiotics or antifungal therapy within 1 month prior to entry into the study 5. use of oral terbinafine or itraconazole within 2 months prior to entry into the study 6. use of immunosuppressive medication or radiation therapy within 3 months prior to entry into the study. 7. confluent, diffuse moccasin-type tinea pedis of the entire plantar surface. 8. presence of any other infection of the foot or other disease process that might confound the treatment evaluation 9. history of dermatophyte infections unresponsive to systemic or topical antifungal drugs 10. known hypersensitivity to naftifine hydrochloride or to any component of the formulation

Keywords: bioequivalence tinea pedis naftin
laeh formulation nasal spray to reduce viral load

Conditions: Coronavirus Disease

Summary: the covixyl-v laeh nasal spray's safety and efficay is clinically tested for use in subjects with covid-19 infection. a randomized, double-blind, multi-center study is conducted to evaluate the efficacy and safety of ethyl lauroyl arginate hydrochloride (laeh) formulation versus a matching placebo formulation administered as a nasal spray to reduce viral load from nasal area of subjects with coronavirus disease 2019 (covid-19).

the primary endpoint for this study was the comparison of change in viral load in rt-pcr test. proportion of covid-19 infection-free subjects between the two treatment arms was followed.

Eligibility criteria:
inclusion criteria: 1. ability to provide written informed consent or, by his or her legal/authorized representatives when the subject is not capable of giving consent, prior to initiation of any study procedures 2. male or female of ≥18 years and ≤65 years of age (inclusive) at time of enrollment 3. subjects with laboratory-confirmed diagnosis of covid-19 at the time of screening (day -3 to 0) using rt pcr method. 4. subject with mild covid-19 symptoms (e.g., fever, cough, sore throat, headache, muscle pain, nasal congestion, rhinorrhea, loss of smell and taste) but who did not have shortness of breath or dyspnea 5. subjects who did not require hospitalization 6. subjects with spo2 levels ≥ 95% 7. viral load by rt-pcr between 3.3 × 106 copies/ml to 6.6 × 106 copies/ml 8. female subject who was not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile 9. female subject of childbearing potential who had negative urine pregnancy test. exclusion criteria: 1. allergy to laeh or any of the excipients of the formulation 2. history of allergies or flu within 30 days prior to the day of enrollment 3. sensitivity to nostril skin or irritation or bleeding history within 30 days prior to the day of enrollment 4. females who were breast-feeding, lactating, pregnant or intending to become pregnant 5. covid-19 subjects with moderate, severe or critical illness or requiring intensive care or mechanical ventilation 6. history of severe respiratory disease and requirement for long-term oxygen therapy 7. had received antibiotic/s, antiviral drug, and hormonal drugs within 30 days prior to the day of enrollment 8. any condition or disease detected during the medical interview/physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the investigator 9. had received or had a plan to receive a sars-cov-2 vaccine during the study period 10. participated in any interventional drug or medical device trials within 30 days prior to the day of enrollment.
studies of the variable phenotypic presentations of rapid-onset dystonia parkinsonism and other movement disorders

Conditions: Dystonia; Parkinsonism

Summary: the purposes of this study are to identify persons with rapid-onset dystonia-parkinsonism (rdp) or mutations of the rdp gene, document prevalence of the disease, and map its natural history.

rapid-onset dystonia-parkinsonism (rdp) is a rare, movement disorder with variable characteristics ranging from sudden onset (hours to days) of severe dystonic spasms to gradual onset of writer's cramp. rdp has elements of both dystonia and parkinson's disease-two neurological diseases with motor and neuropsychological symptoms that hinder the quality of life. an internal trigger associated with extreme physiological stress has been reported prior to abrupt symptom onset of rdp. this study, which is a continuation of an earlier study begun by dr. allison brashear, aims to more clearly identify the characteristics associated with rdp and to explore whether mutations in the rdp gene are associated with atypical dystonias, parkinson's disease, and other movement disorders. the study involves in-person or remote (telemedicine) neurological assessments and blood samples for genetic analysis.

Eligibility criteria:
inclusion criteria: * clinical presentation consistent with atp1a3 disease (rdp, ahc) or confirmed diagnosis of rdp or ahc exclusion criteria: * none

Keywords: dystonia parkinsonism rapid-onset dystonia-parkinsonism rdp alternating hemiplegia of childhood ahc
assessing durvalumab and flot chemotherapy in resectable gastric and gastroesophageal junction cancer

Conditions: Gastrointestinal Neoplasms; Esophagogastric Junction

Summary: this is a global study of neoadjuvant-adjuvant durvalumab or placebo and flot chemotherapy followed by adjuvant durvalumab or placebo in patients with resectable gastric and gastroesophageal cancer (gc/gejc) (matterhorn).

this study investigates treatment of durvalumab or placebo therapy combined with flot chemotherapy (flurouroacil + leucovorin + oxaliplatin + docetaxel) given before surgery (neoadjuvant) and durvalumab or placebo therapy combined with flot chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer, and also to better understand the studied disease and associated health problems.

Eligibility criteria:
key inclusion criteria: * patients with histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (stage ii or higher per ajcc 8th edition). * patients must undergo radical surgery. * no prior anti-cancer therapy for the current malignancy. * world health organization (who)/ecog performance status of 0 or 1 at enrollment. * adequate organ and marrow function. * availability of tumor sample prior to study entry. * must have a life expectancy of at least 24 weeks. key exclusion criteria: * patients with peritoneal dissemination or distant metastasis. * patients with adenosquamous cell carcinoma, squamous cell carcinoma, or gi stromal tumor. * current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. * contra-indication to any of the study drugs. * history of allogeneic organ transplantation.
probiotics in mild alzheimer's disease

Conditions: Neurodegenerative Diseases; Cognition Disorders in Old Age

Summary: the main objective is to investigate whether administration of probiotics to patients with mild alzheimer's disease (ad) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).

we will measure specific blood inflammatory markers (primary outcome), neurophysiological activity, cognitive test scores, microbiome composition and dietary habits of participants in the probiotics and placebo group.

Eligibility criteria:
inclusion criteria: * adults ≥65 years, able to give consent * mini-mental state examination (mmse) scores 19-23 (mild ad) * approximately equal male:female ratio exclusion criteria: * inability to give consent * other neurological disease * relevant psychiatric disorders (e.g. major depression) * gastrointestinal/metabolic conditions * history of alcohol/substance dependence * use of systemic antibiotics in the previous 6 months * corticosteroid use * immune stimulating medications * immunosuppressive agents * probiotics consumption in the previous 6 months. * immunosuppression * structural heart disease * neutropenia * radiation * active intestinal disease

Keywords: probiotics electroencephalogram (eeg) cognitive function alzheimer's disease neuropsychological testing electrocardiogram (ekg)
effectiveness of digital health management on patients with head and neck vascular stenosis

Conditions: Head and Neck Vascular Stenosis

Summary: the purpose of this study is to evaluate the effectiveness of digital health management for intervention on chinese population with head and neck vascular stenosis.


Eligibility criteria:
inclusion criteria: 1. inclusion criteria of the clusters hospitals with the qualification of "head and neck ultrasound center" in china. 2. inclusion criteria for individuals * (1)age ≥ 35 years old, with no restriction on gender. * (2)patients with clinically diagnosed head and neck stenosis or occlusion, including mild, moderate or severe stenosis or occlusion of the carotid artery and mild, moderate or severe stenosis or occlusion of the intracranial artery. * (3)ability to use a smartphone and have a mobile application installed on the handset. * (4)subjects or their legal representatives agreed to the study and signed the project informed consent form. exclusion criteria: 1. exclusion criteria for the clusters the included centers did not have the capacity to undertake the trial. 2. exclusion criteria for individuals * (1)combination of severe systemic diseases such as respiratory failure, renal failure, gastrointestinal bleeding, coagulation dysfunction, malignancy, etc. * (2)patients with a life expectancy of less than 2 years or who are unable to complete the study for other reasons.

Keywords: head and neck vascular stenosis digital health management
tezepelumab treatment in korean severe asthma patients

Conditions: Asthma

Summary: there is no study that systematically evaluated the effect of tezepelumab on cough, and based on this background, the present researchers aimed to evaluate the effect of tezepelumab treatment in patients with severe asthma who complain of cough using the leicester cough questionnaire, a cough-related quality of life measurement tool.


Eligibility criteria:
inclusion criteria: 1. severe asthma patients aged 19 or older and 79 or younger 2. cases diagnosed as asthma by an expert and classified as severe asthma according to the 2014 ats/ers guidelines - patients who require the use of high-dose inhaled steroids and additional control agents or systemic steroids for more than 50% of the year to control symptoms. or, if asthma is not controlled even with the medication. here, uncontrolled asthma means that any one of the following is satisfied. 1. act score less than 20 or 'not well controlled' according to gina guideline 2. frequent exacerbations; requires systemic steroid administration (over 3 consecutive days) more than twice in the previous year if you did 3. severe exacerbation; a condition that required hospitalization, admission to an intensive care unit, or application of a ventilator in the previous year if you have been angry at least once 4. airflow restrictions; fev1 \< 80% 3. if a cough is due to asthma according to a doctor and the cough onset scale (cough visual analogue scale, cough vas) satisfies 30 or more points out of 100. 4. if a positive result is confirmed in the methacholine (or mannitol) bronchial challenge test (if the bronchial challenge test result is not available or the test is difficult to proceed, it can be replaced with a positive bronchodilator response test) exclusion criteria: 1. minors under 19 years of age, senior citizens over 79 years of age 2. if there is a history of use of other biological agents within 3 months prior to study registration 3. cases where there was an acute exacerbation requiring a steroid burst (total 90mg prednisolone or more) during the 4-week screening period before study registration (possible for long-term prednisolone users) 4. cases accompanied by clinically serious respiratory disease in addition to severe asthma 5. when accompanied by hypereosinophilic syndrome, abpa, egpa 6. when it is difficult to evaluate asthma alone due to severe respiratory disease 7. pregnant women
velcade in subjects with relapsed or refractory mantle cell lymphoma

Conditions: Mantle Cell Lymphoma

Summary: the purpose of this study is to find out whether treatment with velcade will increase the time it takes for lymphoma to get worse.

velcade is approved in multiple myeloma for patients who have received two prior therapies and their disease came back or got worse while on their second therapy. velcade is currently being studied in other types of cancers.

Eligibility criteria:
inclusion criteria * 18 years of age or older * confirmed diagnosis of mantle cell lymphoma * documented relapse or progressive disease following 1 or 2 prior lines of anti-cancer therapy. at least one of those regimens must have included an anthracycline or mitoxantrone. relapsed or progressive disease, since last therapy must be documented by new lesions or objective evidence of the progression of existing lesions. * at least 1 measurable or evaluable site of disease * voluntary consent exclusion criteria * previous treatment with velcade * any experimental or anti-cancer therapy within 3 weeks before the first dose of study drug * radiation therapy within 3 weeks before the first dose of study drug * major surgery with 2 weeks before the first dose of study drug * rituximab, campath, or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug * radioimmunotherapy or other toxin immunoconjugates such as zevalin or bexxar within 10 weeks before the first dose of study drug * history of allergic reactions to boron or mannitol compounds * diagnosed or treated for another malignancy other than mantle cell lymphoma with 5 years before the first dose of study drug * active systemic infection requiring treatment * women patients must not be pregnant or breast-feeding, confirmed through pregnancy test obtained during screening (this test is not required for women who are post-menopausal or surgically sterile) * serious medical or psychiatric illness likely to interfere with participation in this clinical study * concurrent treatment with another investigational drug or participation in non-treatment studies is not allowed if it interferes with participation in this clinical study
impact of acute exercise intensity and pattern on cytokine function

Conditions: Inflammation

Summary: the immune system helps prevent illness, fights off infections, and repairs damaged tissues following an injury. however, when immune cells remain active for prolonged periods of time - a state known as "chronic inflammation" - they can contribute to the development and progression of chronic diseases like heart disease and diabetes. exercise can reduce the risk of developing many of these diseases and at least part of the health benefits of exercise are due to the ability of exercise to reduce "chronic inflammation". the inflammation-lowering effects of exercise are typically captured by measuring hormone-like molecules released from immune cells called "cytokines" in the blood. in addition to changes in circulating cytokine levels, exercise may also alter how immune cells respond to these cytokines. how exercise intensity (i.e., how hard you are working during exercise) and pattern (i.e., exercising as a long continuous bout or in short intervals) impact the ability of immune cells to respond to cytokines is not well understood. a better understanding of how exercise intensity and pattern of exercise for reducing chronic inflammation may help determine the best types of exercises for improving health and preventing chronic diseases.


Eligibility criteria:
inclusion criteria: * 18-35 years of age * body mass index between 18.5-30 kg/m\^2 * free of cardiometabolic and autoimmune/inflammatory disease exclusion criteria: * competitive endurance athlete * cigarette smoker * currently taking immunomodulatory/anti-inflammatory medications * currently pregnant

Keywords: exercise cytokines leukocytes interleukin-10 interleukin-6
the core body temperature rhythms: distinguishing mcs from uws

Conditions: Disorders of Consciousness

Summary: in this study, the core body temperature of 7 disorders of consciousness ( doc ) patients were measured every 2 hour for 168 h .

living beings have multicomponent biological rhythms. there was a research recorded 24-h virations in electroencephalographic patterns. in normal subjects, the circadian rhythms of core body temperature is close to 24 h. when the interference of environmental and mental elements were eliminated, circadian rhythm shows the endogenous circadian rhythm of body acquiescently (\>24h ), which is also called free-running period. measuring the continuous external auditory canal temperature of 4 unresponsive wakefulness syndrome (uws) and 3 minimally conscious state(mcs) on the fluorescent lamp surrounding every 2 hours for 168 hours starting at 00:00 on the first day to address circadian capabilities. researchers expected to see the difference between mcs and uws.

Eligibility criteria:
inclusion criteria: * patients in minimally conscious state * patients with stable condition * patients free of sedative drugs and na+ or ca++ blockers (e.g., carbamazepine) or nmda receptor antagonist (e.g., dextromethorphan) exclusion criteria: * premorbid neurology antecedent * patients in coma or vegetative state * patients \< 1 months after the acute brain injury

Keywords: unresponsive wakefulness syndrome minimally conscious state circadian rhythms free-running period